5 Stocks That Turned $5,000 Into $25,907 in Just One Year

Tracking Period: April 25, 2025 – April 25, 2026 Average Yield: 418.14%

What if you had split $5,000 evenly across five carefully chosen stocks just one year ago? According to our tracked performance data, that $5,000 would have grown to $25,907 — a gain of more than 400% in twelve months. These weren't lottery tickets. Each of these stocks had a story, a catalyst, and a reason to run. Here's a breakdown of the five top performers and exactly what drove their extraordinary gains.

1. Celcuity Inc. (NASDAQ: CELC) — +1,016.51%

Celcuity was the undisputed star of this 12-month window, delivering a gain of over 1,000%. The Minneapolis-based clinical-stage biotech had one clear reason for its meteoric rise: gedatolisib, a pan-PI3K/mTOR inhibitor being developed as a treatment for HR+/HER2-negative advanced breast cancer.

The stock's rally was built on a series of escalating clinical and regulatory milestones. First, the company's Phase 3 VIKTORIA-1 trial demonstrated statistically significant improvements in progression-free survival for patients treated with gedatolisib versus standard therapies. Then, in January 2026, the FDA accepted Celcuity's New Drug Application and granted Priority Review for gedatolisib, assigning a PDUFA goal date of July 2026. That looming regulatory decision triggered a wave of institutional buying, as funds typically position into de-risked biotech stocks three to four months ahead of a potential approval decision.

The momentum only accelerated from there. In May 2026, additional Phase 3 data from the PIK3CA-mutant cohort of VIKTORIA-1 met its primary endpoint, reinforcing the drug's commercial outlook and signaling a potential label expansion. Analysts responded by raising price targets aggressively — from Stifel boosting its target to $125 to Citizens initiating coverage with an Outperform rating. Celcuity also strengthened its balance sheet ahead of a potential commercial launch, adding $30 million in debt financing and expanding its commercial headcount, signaling the company's transition from a research lab to a revenue-generating enterprise.

For investors, Celcuity is a textbook case of genuine clinical progress — not hype — driving a multi-bagger return.

2. Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS) — +22.65%

Tarsus Pharmaceuticals was the steadiest performer of the five, delivering a solid 22.65% gain underpinned by the continued commercial success of XDEMVY (lotilaner ophthalmic solution) — the first and only FDA-approved treatment for Demodex blepharitis, a common but chronically undertreated eye condition caused by mite infestation.

XDEMVY's commercial ramp was exceptional by any standard. In its first full year post-FDA approval (2024), the drug generated $183 million in net product sales. By 2025, that figure exploded to $451.4 million — a jump of approximately 150% year-over-year. The company crossed the $100 million per quarter milestone in Q3 2025, with Q4 2025 sales reaching $151.7 million, beating consensus estimates. A direct-to-consumer advertising campaign on streaming platforms and network television generated a positive return on investment, driving patient awareness of Demodex blepharitis to approximately 25% on an unaided basis.

Looking ahead, management guided 2026 revenue to $670–$700 million and reiterated XDEMVY's potential for more than $2 billion in peak sales — a figure that, if achieved, would represent one of the most successful ophthalmic drug launches in history. International expansion is also underway, with potential approval in China anticipated in 2026 and a preservative-free formulation targeting European approval in 2027. The company is also advancing TP-04 in a Phase 2 trial for ocular rosacea and plans to initiate a Phase 2 study of TP-05 for Lyme disease prevention.

Six analysts covering TARS maintain a consensus "Buy" rating with an average price target of $89. With high gross margins (~93%), a growing installed patient base, and a multi-indication pipeline, Tarsus is building what looks like a durable franchise in eye care.

3. Silvercorp Metals Inc. (NYSE American: SVM) — +236.29%

While biotech and tech stocks grabbed headlines, Silvercorp Metals quietly delivered a 236% return by riding one of the most powerful macro tailwinds of 2025 and 2026: the bull market in silver and precious metals.

Silvercorp, which operates primarily in China as that country's top primary silver producer, benefited enormously from silver spot prices surging past $90 an ounce — levels not seen in decades. That price appreciation directly flowed through to Silvercorp's financials. For fiscal year 2026, the company produced 6.8 million ounces of silver and generated revenue of $438.1 million, representing a 47% increase over fiscal 2025. Q3 2026 revenue alone jumped 51% year-over-year to $126.1 million.

Beyond the silver price tailwind, Silvercorp demonstrated strong fundamentals: an EBIT margin above 33%, minimal long-term debt (a debt-to-equity ratio of just 0.16), and robust operating cash flow. The company maintained its semi-annual dividend, reinforcing investor confidence, and continued advancing construction at its Kuanping and El Domo mines, signaling future production growth. Analysts at BMO Capital and Raymond James both raised their price targets significantly — to C$17.50 and C$17, respectively — each maintaining Outperform ratings.

Silvercorp was a straightforward thesis: a well-run, low-cost silver miner operating in an environment where the price of its primary product nearly doubled. For investors seeking commodity-driven returns with real earnings to back them up, SVM delivered.

4. IES Holdings, Inc. (NASDAQ: IESC) — +199.66%

IES Holdings may be the least-known name on this list, but its nearly 200% gain was backed by some of the most consistently impressive fundamental performance of any company in this group. The Houston-based electrical and technology infrastructure services company became one of the clearest beneficiaries of the AI and data center construction boom.

The numbers tell the story with precision. In fiscal year 2025, IES grew consolidated revenue by 17% to $3.37 billion, with its Communications segment — which serves data center customers — surging 47% to $1.14 billion. Operating income climbed 27% for the full year. The company then carried that momentum into fiscal 2026: Q1 revenue rose 16% to $871 million with operating income jumping 31%, and Q2 revenue climbed another 17% to $974 million with net income surging 56% to $109.9 million, or $5.44 per diluted share.

Perhaps most telling for future growth: IES's backlog expanded to approximately $3.9 billion as of March 2026 — a 62% increase since the end of fiscal 2025. Remaining performance obligations stood at around $2.3 billion. As management noted, customers were actively accelerating their orders and expanding the scope of their contracts.

IES also made a strategic acquisition during the period, completing the purchase of Gulf Island Fabrication in January 2026, a leading steel fabricator serving industrial, energy, and government sectors, which further diversified its revenue base and contributed $37.5 million in revenue in its first quarter of contribution.

In a world increasingly powered by artificial intelligence, IES Holdings was quietly building the physical infrastructure that makes it all possible — and investors who recognized that early were handsomely rewarded.

5. Opendoor Technologies Inc. (NASDAQ: OPEN) — +615.58%

Opendoor's 615% rise was one of the most dramatic and complex stories in this group. The San Francisco-based iBuying platform — which buys, renovates, and resells homes through its online marketplace — had been left for dead by Wall Street, trading near penny-stock territory in mid-2025. What followed was a remarkable combination of retail investor enthusiasm, genuine operational improvement, and favorable macro policy shifts.

The turnaround story truly began when new CEO Kaz Nejatian took the helm and moved the company into what he called "founder mode," prioritizing AI-powered efficiencies and a leaner operational structure. Retail traders on Reddit and X (formerly Twitter) took notice, piling into the stock in a frenzy — but with one key difference from prior meme stocks: Opendoor's fundamentals were actually improving underneath the surface.

By Q4 2025, Opendoor reported $736 million in revenue — beating Wall Street's consensus estimate by nearly 24%. Home acquisitions jumped 46% quarter-over-quarter, and homes under contract surged more than 300%. The CEO publicly noted that the October 2025 acquisition cohort was on track to be the strongest-performing October cohort in company history, with homes selling at twice the velocity of the prior year's cohort. These were real results, not just promises.

A macro tailwind then amplified the move further. A White House executive order deregulating the mortgage industry and expanding credit access dropped in March 2026, directly expanding the addressable pool of potential transactions for Opendoor's platform. The company also launched a 4.99% beta mortgage program in tandem. JPMorgan responded with an Overweight rating and an $8 price target, and the stock continued its ascent.

Opendoor remains a high-risk, high-volatility stock, but for those positioned early, the reward was extraordinary.

The System Behind These Picks: GrowthTech.ai

These five stocks weren't found by luck or gut instinct — they were identified by GrowthTech.ai, an AI-powered stock intelligence platform built for everyday investors who want an edge without spending hours glued to financial news.

GrowthTech.ai's proprietary BullsEye Market Intelligence System analyzes thousands of live market variables every day — momentum, volatility, capital flows, and trend strength — to surface the strongest stock and crypto opportunities before the broader market catches on. The result? A clean, simple dashboard that tells you what to buy, and when to sell. No financial jargon. No overwhelming charts. Just clarity.

How It Works

Login → View the top-ranked stocks and crypto → Invest via your current brokerage → Follow the exit plan

That's it. No new brokerage accounts to open. No trading experience required.

GrowthTech.ai doesn't manage your funds, doesn't execute trades, and doesn't take broker commissions. Their only incentive is delivering accurate, unbiased rankings to their members — over 5,000 of them and growing.

What You Get

• Daily AI-powered stock and crypto rankings

• A clear exit plan — so you know when to sell, not just when to buy

• A distraction-free dashboard updated every day

• Full platform access with no long-term commitment
  

Pricing: $79/month, or $790/year (equivalent to two months free). Cancel anytime.

With 12+ years of experience, a 4.5/5 rating on Trustpilot, and a verified track record that includes calls like the five stocks above, GrowthTech.ai is designed for one purpose: helping independent investors make smarter, more profitable decisions.

→ See Today's Top Stocks at GrowthTech.ai

The Takeaway: Five Different Stories, One Common Thread

What made these five stocks work over this 12-month period? Each had a distinct catalyst:

• Celcuity had breakthrough clinical data and an FDA Priority Review turning it into a pre-commercial biotech with genuine blockbuster potential.

• Tarsus Pharmaceuticals had XDEMVY — the only approved drug for a condition affecting tens of millions of Americans — and a commercial ramp that exceeded nearly every expectation.

• Silvercorp had silver prices at multi-decade highs and a well-run operation producing more metal at lower cost.

• IES Holdings had the data center construction boom and a backlog that kept growing quarter after quarter.

• Opendoor had a new CEO, improving operational metrics, and a retail tailwind fueled by real Q4 results that surprised to the upside.
  

The lesson isn't that hindsight makes stock picking easy — it doesn't. But with the right system analyzing the right signals at the right time, patterns emerge well before the rest of the market catches on. That's exactly what GrowthTech.ai is built to do.

Ready to see what the AI is ranking today? Visit GrowthTech.ai →

Past performance is not indicative of future results. This article is for informational and educational purposes only and does not constitute financial or investment advice. GrowthTech.ai does not give out individual financial or investment advice or act as a personal financial advisor. Always conduct your own due diligence and consult a qualified financial advisor before making investment decisions.